Developing mRNA medicines to restore protein function.

We are a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.

Learn More

Translate Bio

We are pioneering the translation of mRNA therapeutics into transformative medicines.

Recent News

05.09 2019
Translate Bio Announces First Quarter 2019 Financial Results and Provides Corporate Update
05.01 2019
Translate Bio Announces $47.5 Million Private Placement
04.29 2019
Translate Bio Announces Oral Presentation of mRNA Therapeutics in Models of Metabolic Disorders at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
04.11 2019
Translate Bio Appoints Robert Plenge, M.D., Ph.D., to its Board of Directors

View All

@TranslateBio